High-grade glioma with dural progression: A single-center case series and review of literature Authors: George Wang, Abraham Nirappel, Arashdeep Kaur, Douglas Martin, Prashant Vempati, Tiffany Hodges, Chaitra Badve Published: 2026 ABSTRACT Glioblastoma is the most common and aggressive primary brain tumor in adults. However, despite its aggressive nature, dural-based progression remains exceedingly rare. This rarity is partially due to the protective effects of the blood-brain barrier and the poor survival of affected patients. As a result, the pathophysiology and imaging characteristics of dural-based glioblastoma progression remain poorly understood and underreported. In this case series, we present 4 cases of glioblastoma with dural-based progression and review the relevant literature. We highlight the MRI imaging features of dural progression and explore potential pathophysiology, diagnosis, and management in this rare manifestation. Introduction Glioblastoma (GBM) is an aggressive brain tumor associated with poor overall survival [1,2]. Despite its aggressive nature, dural progression is extremely rare, occurring in less than 2% of cases [3]. This rarity has been attributed to its limited access to the lymphatic and vascular systems and the short survival time of affected patients [4]. However, with advances in multimodality treatment and modest improvements in survival, uncommon patterns of spread, such as dural progression, are being encountered more frequently [5]. The mechanisms underlying dural dissemination remain poorly understood. The most common proposed route is iatrogenic seeding after craniotomy, biopsy, or shunt placement, which may provide tumor cells access to extracranial lymphatic or vascular pathways [6,7]. However, these mechanisms do not explain the occurrence of distant dural progression, remote from the surgical site [[8], [9], [10]]. Distant spread of GBM at sites distant from surgical defects is exceedingly rare but is theorized to occur via perineural invasion along cranial or spinal nerves or through direct dural invasion [11]. Currently, no standardized protocol exists for managing dural based progression in recurrent GBM. Treatment strategies typically mirror those for tumor recurrence, aiming to reduce tumor burden, alleviate neurological symptoms, and minimize medication-related complications [12,13]. Although dural involvement remains rare, improvements in surgical techniques and systemic therapies have extended overall survival, thereby increasing the likelihood of observing dural-based lesions in select patients [14,15]. This underscores the need for further investigation into the radiological and clinical characteristics, underlying pathophysiological mechanisms, and potential treatment options through larger case series. Although several case reports have described dural progression of GBM, the literature remains limited by small numbers, heterogeneous reporting, and a lack of focused synthesis of radiologic patterns, molecular features, and clinical course [3,5,[16], [17], [18], [19], [20]]. A case series paired with a review of literature is therefore valuable because it allows individual observations to be placed in a broader clinical and radiologic context, helping identify patterns that may not be apparent from isolated reports alone. In this case series, we aim to characterize the clinical presentation, imaging features, molecular profiles, and management of GBM with dural progression. Through 4 cases of GBM progression with dural involvement, we aim to define the radiologic patterns of dural dissemination, correlate these findings with relevant molecular and clinicopathologic features, and highlight the potential mechanisms and treatment considerations associated with this uncommon manifestation. By linking clinical observations with imaging, tumor biology, and management considerations, we aim to improve recognition and evaluation of dural involvement in patients with GBM progression. Case report Case one A 65-year-old right-handed male with no significant medical history presented to the emergency room with a left-hand tremor, seizures, and falls. On physical exam, he was alert and oriented × 3, with intact cranial nerves and full strength in all extremities. Brain MRI demonstrated a right temporal lobe mass with adjacent dural thickening and enhancement. The patient underwent 5-ALA-guided right temporoparietal craniotomy with gross total resection (GTR). Histopathologic analysis confirmed GBM, IDH-wildtype, and MGMT promoter unmethylated. He subsequently completed standard chemoradiation followed by 6 cycles of adjuvant temozolomide. At 21 months post-craniotomy, a follow-up MRI showed a new enhancing dural-based lesion overlying the right frontal region, spatially distinct from the surgical cavity. The lesion appeared dural-based with associated dural thickening and heterogeneous enhancement extending into an adjacent sulcus (Figs. 1A and B). Although the lesion was initially favored to represent a meningioma, mild focal uptake on 68Ga-DOTATATE PET/CT (SUVmax = 1.9), together with marked interval enlargement (1.0 × 1.0 × 0.7 cm to 1.6 × 2.3 × 1.4 cm) (Fig. 1C) on a follow-up MRI over 2 months raised concern for GBM progression with dural involvement. Given that this represented an isolated site of recurrence, the lesion was treated with stereotactic radiosurgery (SRS) with a single 20 Gy fraction.Fig. 1A 65-year-old male with GBM progression with dural involvement in the right frontal region. (A) Axial post-contrast T1-weighted MR image obtained 2 mo before the first radiographic evidence of dural involvement. (B) Axial post-contrast T1-weighted MR image at the same level shows new enhancing dural-based disease along the right frontal convexity. (C) Interval axial post-contrast T1-weighted MR image demonstrates marked enlargement of the dural-based enhancing lesion over the subsequent 2 mo. (D) Axial fused 68Ga-DOTATATE PET/MRI image shows mild tracer uptake within the right frontal dural-based lesion. (E) Axial fused FET PET/MRI image demonstrates increased amino-acid tracer uptake in the corresponding region (blue ROI), concerning for viable tumor. (F) Axial post-contrast T1-weighted MR image obtained 1 y after SRS—following an interval period of radiographic remission—demonstrates new dural-based enhancement concerning for recurrent disease. (G) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia.Fig 1 – dummy alt text A 65-year-old male with GBM progression with dural involvement in the right frontal region. (A) Axial post-contrast T1-weighted MR image obtained 2 mo before the first radiographic evidence of dural involvement. (B) Axial post-contrast T1-weighted MR image at the same level shows new enhancing dural-based disease along the right frontal convexity. (C) Interval axial post-contrast T1-weighted MR image demonstrates marked enlargement of the dural-based enhancing lesion over the subsequent 2 mo. (D) Axial fused 68Ga-DOTATATE PET/MRI image shows mild tracer uptake within the right frontal dural-based lesion. (E) Axial fused FET PET/MRI image demonstrates increased amino-acid tracer uptake in the corresponding region (blue ROI), concerning for viable tumor. (F) Axial post-contrast T1-weighted MR image obtained 1 y after SRS—following an interval period of radiographic remission—demonstrates new dural-based enhancement concerning for recurrent disease. (G) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia. One year after SRS, a follow-up MRI demonstrated a new focal nodular dural-based enhancing lesion at the same site. FET and DOTATATE PET were performed and demonstrated a metabolically active disease (FET SUVmax = 4.3; DOTATATE SUVmax = 3.7) (Figs. 1D and E), again concerning for a GBM progression with dural involvement. Follow-up MRI 2 months later showed marked interval growth (1.9 × 1.1 × 1.5 cm to 2.8 × 3.1 × 2.7 cm) (Fig. 1F), further supporting progressive disease. On the basis of the imaging progression and concordant PET findings, the tumor board recommended repeat 5-ALA-guided right frontal craniotomy with GTR. Histopathology confirmed GBM progression with dural involvement (Fig. 1G). At the time of submission, 11 months after the second craniotomy, the patient remained clinically well with stable disease on surveillance MRI (Tables 1 and 2).Table 1Summary of demographics, primary tumor features, time to dural-based progression, imaging findings, management, and outcomes.Table 1 – dummy alt textCase1234Age/Sex65/M61/F77/F33/FPathologyGrade IV IDH WT GBMGrade IV IDH WT GBMGrade IV IDH WT GBMGrade IV IDH WT GBMMGMT statusUnmethylatedUnmethylatedUnmethylatedUnmethylatedInitial surgery5-ALA-guided GTR5-ALA-guided GTR5-ALA-guided GTR5-ALA-guided GTRInitial CCRT60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZInitial adjuvant therapy6 cycles of TMZ2 cycles of TMZ4 cycles of TMZ + TTF6 cycles of TMZPrimary tumor siteR temporalR temporalR frontalL parietalDural involvement siteR frontalR frontalR temporalL frontalDural tumor focalityUnifocalUnifocalUnifocalUnifocal/DiffusedDural involvement relative to surgical cavityRemote, IpsilateralRemote, IpsilateralRemote, IpsilateralRemote, IpsilateralDural based progression managementFirst recurrence/KPSSRS with 20 Gy/100Hospice care/502x LITT/60LITT, Avastin, CCNU/80Second recurrence/KPS5-ALA-guided GTR/100Time from initial histopathologic diagnosis to dural based progressionFirst dural progression21 mo8 mo10 mo14 moSecond dural progression33 moOverall survival44 mo/Alive12 mo13 mo22 moCCNU, lomustine; CCRT, concurrent chemoradiotherapy; F, female; GTR, gross total resection; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; LITT, laser interstitial thermal therapy; M, male; R, right; SRS, stereotactic radiosurgery; Fx, fraction; TMZ, temozolomide; WT, wild type.Table 2Case reports of glioblastoma with dural progression.Table 2 – dummy alt textStudyAge, sexTumor focalityRelationship to surgical cavityTreatmentKwak et al. [5]53, MUnifocalAdjacentReresectionNagatani et al. [18]63, FUnifocalAdjacentReresectionLettau et al. [19]80, MMultifocalRemoteReresectionKonar et al. [16]59, FUnifocalRemoteReresectionHintenlang et al. [34]64, MUnifocalRemoteSRS + adjuvant TMZMichaelson et al. [20]63, MUnifocalAdjacentReresectionKleinschmidt-DeMasters et al. [35]70, MMultifocalRemoteRadiation + chemotherapyF, female; M, male; SRS, stereotactic radiosurgery; TMZ, temozolomide. Table 1Summary of demographics, primary tumor features, time to dural-based progression, imaging findings, management, and outcomes.Table 1 – dummy alt textCase1234Age/Sex65/M61/F77/F33/FPathologyGrade IV IDH WT GBMGrade IV IDH WT GBMGrade IV IDH WT GBMGrade IV IDH WT GBMMGMT statusUnmethylatedUnmethylatedUnmethylatedUnmethylatedInitial surgery5-ALA-guided GTR5-ALA-guided GTR5-ALA-guided GTR5-ALA-guided GTRInitial CCRT60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZ60 Gy in 10 fx with TMZInitial adjuvant therapy6 cycles of TMZ2 cycles of TMZ4 cycles of TMZ + TTF6 cycles of TMZPrimary tumor siteR temporalR temporalR frontalL parietalDural involvement siteR frontalR frontalR temporalL frontalDural tumor focalityUnifocalUnifocalUnifocalUnifocal/DiffusedDural involvement relative to surgical cavityRemote, IpsilateralRemote, IpsilateralRemote, IpsilateralRemote, IpsilateralDural based progression managementFirst recurrence/KPSSRS with 20 Gy/100Hospice care/502x LITT/60LITT, Avastin, CCNU/80Second recurrence/KPS5-ALA-guided GTR/100Time from initial histopathologic diagnosis to dural based progressionFirst dural progression21 mo8 mo10 mo14 moSecond dural progression33 moOverall survival44 mo/Alive12 mo13 mo22 moCCNU, lomustine; CCRT, concurrent chemoradiotherapy; F, female; GTR, gross total resection; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; LITT, laser interstitial thermal therapy; M, male; R, right; SRS, stereotactic radiosurgery; Fx, fraction; TMZ, temozolomide; WT, wild type. Summary of demographics, primary tumor features, time to dural-based progression, imaging findings, management, and outcomes. CCNU, lomustine; CCRT, concurrent chemoradiotherapy; F, female; GTR, gross total resection; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; LITT, laser interstitial thermal therapy; M, male; R, right; SRS, stereotactic radiosurgery; Fx, fraction; TMZ, temozolomide; WT, wild type. Table 2Case reports of glioblastoma with dural progression.Table 2 – dummy alt textStudyAge, sexTumor focalityRelationship to surgical cavityTreatmentKwak et al. [5]53, MUnifocalAdjacentReresectionNagatani et al. [18]63, FUnifocalAdjacentReresectionLettau et al. [19]80, MMultifocalRemoteReresectionKonar et al. [16]59, FUnifocalRemoteReresectionHintenlang et al. [34]64, MUnifocalRemoteSRS + adjuvant TMZMichaelson et al. [20]63, MUnifocalAdjacentReresectionKleinschmidt-DeMasters et al. [35]70, MMultifocalRemoteRadiation + chemotherapyF, female; M, male; SRS, stereotactic radiosurgery; TMZ, temozolomide. Case reports of glioblastoma with dural progression. F, female; M, male; SRS, stereotactic radiosurgery; TMZ, temozolomide. Case two A 61-year-old right-handed female with no significant past medical history presented to the emergency department with headaches and photopsias. On physical exam, she was alert and oriented × 3, with intact cranial nerves and full motor strength in all extremities. Brain MRI demonstrated a right temporal lobe mass. The patient underwent 5-ALA-guided right temporoparietal craniotomy with GTR. The postoperative course was complicated by intraparenchymal and intraventricular hemorrhage, requiring external ventricular drain placement. Histopathologic analysis confirmed GBM, IDH-wildtype, and MGMT promoter unmethylated. She subsequently completed standard chemoradiation followed by 2 cycles of adjuvant temozolomide. At 8 months post-craniotomy, a follow-up MRI showed a new enhancing dural-based lesion overlying the right frontal lobe (Figs. 2A and B). The lesion demonstrated an elevated rCBV of 4.9 on perfusion MRI, raising concern for GBM progression with dural involvement. Follow-up MRI 2 months later showed marked interval growth of the dural-based nodule (2.4 × 1.2 × 2.3 cm to 4.5 × 5.3 × 3.3 cm), with invasion into the right frontal lobe and operculum (Figs. 2 C and D). FLAIR signal abnormalities extended to the right frontal lobe, anterior temporal lobe, and insula. Leptomeningeal enhancement had also progressed to involve the right sylvian fissure. The dominant nodular dural-based morphology, elevated rCBV, and aggressive interval growth favored dural GBM progression. Given the extent of disease progression and the patient’s poor Karnofsky Performance Status (KPS) score (50), the patient declined further aggressive treatment and was discharged to hospice care.Fig. 2A 61-year-old female with GBM progression with dural involvement. (A) Axial post-contrast T1-weighted MR image obtained 2 mo before the first radiographic evidence of dural involvement. (B) Axial T1 post-contrast image from a follow-up scan reveals a new dural-based lesion overlying the right frontal lobe inferior to the resection site. (C) Coronal T1 post-contrast image confirms the presence of the same dural-based lesion. (D) Axial T1 post-contrast image obtained 3 mo later shows significant growth of the enhancing nodule, now invading the right frontal lobe and frontal operculum. (E) Coronal T1 post-contrast image further demonstrates the lesion’s substantial progression with invasion into the brain parenchyma.Fig 2 – dummy alt text A 61-year-old female with GBM progression with dural involvement. (A) Axial post-contrast T1-weighted MR image obtained 2 mo before the first radiographic evidence of dural involvement. (B) Axial T1 post-contrast image from a follow-up scan reveals a new dural-based lesion overlying the right frontal lobe inferior to the resection site. (C) Coronal T1 post-contrast image confirms the presence of the same dural-based lesion. (D) Axial T1 post-contrast image obtained 3 mo later shows significant growth of the enhancing nodule, now invading the right frontal lobe and frontal operculum. (E) Coronal T1 post-contrast image further demonstrates the lesion’s substantial progression with invasion into the brain parenchyma. Case three A 77-year-old right-handed female with a history of hypertension, type 2 diabetes mellitus, and hyperparathyroidism presented to the emergency room with aphasia and confusion. On physical exam, she was alert and oriented × 3, with intact cranial nerves and full strength in all extremities. Brain MRI demonstrated a right frontal lobe mass with adjacent dural thickening and enhancement. The patient underwent 5-ALA-guided right pterional craniotomy with GTR. Histopathologic analysis confirmed GBM, IDH-wildtype, and MGMT promoter unmethylated. She subsequently underwent standard concurrent chemoradiation with temozolomide, followed by 4 cycles of adjuvant temozolomide with concurrent tumor treating fields. At 10 months post-craniotomy, a follow-up MRI showed a new enhancing dural-based lesion overlying the right temporal lobe (Fig. 3B) and a lesion in the right frontal lobe. The lesion demonstrated an elevated rCBV of 3.4 on perfusion MRI, raising concern for GBM progression with dural involvement. Given the patient’s age and comorbidities, the multidisciplinary team and family elected to proceed with right-sided stereotactic biopsy and laser interstitial thermal therapies (LITT) for the 2 lesions. Surgical pathology confirmed GBM progression with dural involvement (Fig. 3D). Two months post-LITT, MRI demonstrated marked progression of the right temporal dural-based lesion, with irregular nodular enhancement extending medially along the right tentorium (Fig. 3C). In view of the rapid disease progression and limited expected benefit of further aggressive therapy, the patient elected to forego additional treatment and was transitioned to hospice care.Fig. 3A 77-year-old female with GBM progression with dural involvement. (A) Axial T1 post-contrast image taken 2 mo before the first signs of dural involvement. (B) Corresponding axial contrast-enhanced T1-weighted image at the time of first dural involvement demonstrates a new T1-hyperintense dural-based lesion along the inferolateral margin of the right temporal lobe, prior to LITT. (C) Axial contrast-enhanced T1-weighted image acquired 2 mo after LITT shows interval enlargement of the enhancing dural nodule, consistent with GBM progression with dural involvement. (D) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia.Fig 3 – dummy alt text A 77-year-old female with GBM progression with dural involvement. (A) Axial T1 post-contrast image taken 2 mo before the first signs of dural involvement. (B) Corresponding axial contrast-enhanced T1-weighted image at the time of first dural involvement demonstrates a new T1-hyperintense dural-based lesion along the inferolateral margin of the right temporal lobe, prior to LITT. (C) Axial contrast-enhanced T1-weighted image acquired 2 mo after LITT shows interval enlargement of the enhancing dural nodule, consistent with GBM progression with dural involvement. (D) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia. Case four A 33-year-old right-handed female with no significant medical history presented to the emergency department with a 2-week history of falls and new-onset seizures. On physical exam, she was alert and oriented × 3, with intact cranial nerves and full strength in all extremities. Brain MRI demonstrated a left parietal parasagittal mass with an exophytic dural-based component. The patient underwent 5-ALA-guided left temporoparietal craniotomy with GTR. Histopathologic analysis confirmed GBM, IDH-wildtype, and MGMT promoter unmethylated. He subsequently completed standard chemoradiation followed by 6 cycles of adjuvant temozolomide. At 14 months post-craniotomy, a follow-up MRI showed 2 new enhancing masses in the left parasagittal frontoparietal lobe and left parasagittal frontal lobe. A new dual-based mass within the anterior cranial fossa overlying the left frontal lobe. PET imaging demonstrated corresponding hypermetabolic activity with a SUVmax of 10.6, raising concern for GBM progression with dural involvement. The Multidisciplinary Tumor Board recommended a stereotactic biopsy and LITT; pathology confirmed recurrent GBM. Six months post-LITT, a follow-up MRI demonstrated marked progression of enhancing masses in the left parasagittal frontoparietal lobe and left parasagittal frontal lobe (Fig. 4B). The dural-based lesion overlying the left frontal lobe also showed substantial interval enlargement (1.1 × 1.1 × 0.9 cm to 3.8 × 7.9 × 2.2 cm) with associated diffuse dural thickening and enhancement along the left cerebral convexity, extending from the frontal to the occipital region (Fig. 4C). Stereotactic biopsy of the dural lesion confirmed progressive GBM with dural involvement (Fig. 4D). Despite the patient’s relatively young age, the rapid progression and diffuse extent of disease precluded further surgical intervention. She was subsequently treated with Lomustine and Bevacizumab but died 3 months later.Fig. 4A 33-year-old female with dural GBM progression with dural involvement. (A) Axial T1 post-contrast image taken 2 mo before the first signs of dural involvement. (B) Axial postcontrast T1-weighted image at the time of dural progression demonstrates two new enhancing parasagittal lesions in the left frontal and parietal lobes. (C) Axial postcontrast T1-weighted image shows a large, poorly enhancing, predominantly necrotic dural-based frontal convexity lesion with associated diffuse dural thickening (*) and enhancement, compatible with widespread dural involvement remote from the original resection site. (D) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia.Fig 4 – dummy alt text A 33-year-old female with dural GBM progression with dural involvement. (A) Axial T1 post-contrast image taken 2 mo before the first signs of dural involvement. (B) Axial postcontrast T1-weighted image at the time of dural progression demonstrates two new enhancing parasagittal lesions in the left frontal and parietal lobes. (C) Axial postcontrast T1-weighted image shows a large, poorly enhancing, predominantly necrotic dural-based frontal convexity lesion with associated diffuse dural thickening (*) and enhancement, compatible with widespread dural involvement remote from the original resection site. (D) (400x), H&E staining of the dural base lesion demonstrates diffuse reactivity for GFAP and Olig2 and highly anaplastic glial cells with nuclear atypia. Discussion GBM is an aggressive brain tumor characterized by rapid tumor cell growth and diffuse infiltration [1,2]. Despite its tendency to spread throughout the brain, dural involvement is extremely rare [3]. This rarity can be attributed to the poor survival of the affected patients and the lack of access of tumor cells to the lymphatic and vascular systems [3]. Notable observations from our case series include the spatial pattern of dural progression in relation to the primary tumor. All 4 patients have their dural progression remote from the surgical cavity with initial tumors located on the superficial aspect of the cortex. In addition, all dural lesions were ipsilateral to the primary tumor, and all patients had undergone 1 prior craniotomy before the diagnosis of dural GBM progression. These findings are consistent with prior reports describing dural involvement most commonly after craniotomy [21,22]. However, although this pattern suggests surgical disruption may contribute to dural dissemination, our data are insufficient to establish causality and should be considered hypothesis-generating. One important baseline diagnosis to consider when evaluating dural involvement in patients with GBM is a history of gliosarcoma. Compared to GBM, gliosarcomas demonstrate a significantly higher propensity for extracranial dissemination, reported in up to 30% of cases [23]. In our cohort, none of the patients were diagnosed with gliosarcoma, nor was sarcomatous differentiation identified on histopathological review. GBM progression with dural involvement is rare and may closely mimic meningioma on conventional imaging, creating an important diagnostic challenge [3]. In this setting, 68Ga-DOTATATE PET may provide useful adjunctive information because it targets somatostatin receptor subtype 2 (SSTR2), which is highly expressed in most meningiomas but typically absent or only weakly expressed in GBM [24]. The application of 68Ga-DOTATATE PET was seen in case 1, where the dural-based lesion was initially favored to represent meningioma on a follow-up MRI. However, the lesion demonstrated only mild 68Ga-DOTATATE uptake (SUVmax = 1.9), which was atypical for meningioma and instead raised concern for either GBM progression with dural involvement or treatment-related change. Short-interval follow-up MRI subsequently demonstrated marked interval growth, supporting the diagnosis of dural GBM progression. Although prior studies have shown that 68Ga-DOTATATE PET is highly sensitive for meningioma detection, its specificity for distinguishing meningioma from GBM with dural involvement is imperfect, as high-grade gliomas may occasionally show SSTR2-mediated tracer uptake [[24], [25], [26], [27], [28]]. Kiviniemi et al. [26] reported positive SSTR2A status in 13% of IDH-wildtype GBMs and 27% of IDH-mutant astrocytomas on 68Ga-DOTA-peptide PET/CT. Likewise, Rauschenbach et al. [27] described an extra-axial GBM with focal 68Ga-DOTATATE uptake up to an SUVmax of 8.23. Nevertheless, the degree of uptake remains informative. Rachinger et al. [29] reported an SUVmax threshold of 2.3 on 68Ga-DOTATATE PET for differentiating meningioma from tumor-free tissue, and Hartmann et al. [30] showed that meningiomas typically demonstrate very high DOTATATE uptake (SUVmax ≥10, median 19), whereas GBM usually have SUVmax values less than 5. Applying these thresholds, the relatively low DOTATATE SUVmax values in our patient (1.9 at initial dural recurrence and 3.7 at second dural recurrence) are atypical for meningioma and more compatible with high-grade glioma or treatment-related changes [17,18]. As part of a multimodality diagnostic approach, 68Ga-DOTATATE PET can be pragmatically incorporated into the evaluation of dural-based lesions in patients with GBM to help distinguish tumor progression from meningioma or treatment-related change and, in turn, guide real-time management decisions. When an MRI reveals a new dural-based lesion and meningioma is a consideration, 68Ga-DOTATATE PET can help assess for the strong tracer avidity typically expected in meningioma. Low uptake argues against meningioma and should prompt consideration of GBM progression or treatment-related change, with further evaluation by short-interval MRI and, when available, amino acid PET such as FET PET [17]. As seen during case 1′s second tumor recurrence, FET PET was used and showed a SUVmax of 4.3, exceeding the commonly cited threshold for recurrent high-grade glioma and further supporting recurrence over treatment effect [17]. Together, these findings suggest that 68Ga-DOTATATE PET and FET PET can serve as complementary molecular imaging tools in the evaluation of dural-based lesions in patients with GBM in real time, improving diagnostic confidence when conventional MRI alone cannot reliably distinguish recurrent tumor from meningioma or treatment-related change. Another important differential diagnosis to consider is the development of radiation-induced meningiomas (RIM), which are typically more clinically aggressive than sporadic meningiomas and can be radiologically mistaken for GBM with dural involvement. RIMs typically arise years to decades after childhood or adolescent cranial irradiation [31]. None of our patients had a history of childhood cancer or sufficient post-treatment survival to be at high risk for RIM. Furthermore, Ellingson et al. [32] reported a median volumetric doubling time of 21.1 to 49.6 days for untreated, preoperative GBM, comparable to the 21-day doubling time observed in our patient in case 1. In contrast, Thomann et al. [33] and Gillespie et al. [31] found that meningiomas grow much more slowly, with median doubling times of 51.7 to 185 months for sporadic cases and 12 to 24 months for RIMs. Nonetheless, in patients with dural-based lesions and prior cranial radiation, RIM should remain an important diagnostic consideration. In our literature review, we were able to find 7 reported cases of GBM with secondary dural progression [5,[18], [19], [20],34,35]. The cases have varied in age (53-70 years; median, 63 years) and have been seen predominantly in males (male/female ratio, 5:2), on the temporal lobe (temporal lobe/total, 5:7), and unifocal in tumor focality (unifocal/multifocal, 5:2). Due to the scarcity of clinical literature on the presentation and management of dural progression in GBM, the optimal treatment remains uncertain. Reported approaches have varied across studies, including surgical resection, radiation therapy, temozolomide chemotherapy, and stereotactic radiosurgery (SRS) [5,[18], [19], [20],34,35]. Prognoses and outcomes have been highly variable, with some cases showing near-complete resolution of dural GBM after SRS, while others presented with further dural spread following re-resection [5,[18], [19], [20],34,35]. Hintelang et al. [34] demonstrated the successful use of SRS in treating dural involvement in GBM, achieving near-complete resolution for up to 13 months. In the present case series, treatment approaches varied among patients. Among the 4 patients, only the patient who received SRS followed by re-resection achieved sustained disease control, with near-complete resolution for at least 12 months from the date of confirmed dural progression. In this case, the lesion was also treated promptly with a relatively small lesion size and lack of diffuse dural involvement. In contrast, the remaining 3 patients, who had passed away at the time of chart review, had a larger disease burden, extensive dural involvement, and a median survival of 4 months following the diagnosis of dural progression. These findings suggest that all dural lesions in GBM patients need to be treated with a high index of suspicion, and achieving local control early in the course of the disease may yield better long-term outcomes. Due to the retrospective design and small sample size inherent to a case series, a few limitations warrant consideration. First, selection bias is possible because all patients were identified from a single institution, which may underrepresent the broader spectrum of dural involvement in GBM. Second, despite our effort to include cases with similar tumor pathology and initial treatment, each case remained inherently distinct with respect to tumor location, complications related to initial therapy, patient functional status, and underlying tumor aggressiveness, all of which contributed to heterogeneity in imaging follow-up and treatment strategies across patients. In conclusion, GBM with secondary dural progression represents a rare but clinically significant pattern of disease spread that poses substantial diagnostic and therapeutic challenges. In this case series, in conjunction with prior reports, we observed that dural lesions tend to occur ipsilateral to superficially located primary tumors, in the setting of prior craniotomy, and can closely mimic meningioma on imaging. Advanced imaging with 68Ga-DOTATATE PET and FET PET may aid in distinguishing GBM progression with dural involvement from meningioma, particularly in lesions with relatively low DOTATATE uptake and elevated amino acid tracer uptake. Based on our findings, close monitoring of new dural lesions and aggressive early local control of disease may improve disease control and potentially prolong survival. Patient consent A written informed consent was obtained from the patient for the publication of this case report.